Melanoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 years or older.
• People who have been diagnosed with advanced melanoma (stage IIIC or IV) that cannot be surgically removed, confirmed by a tissue sample test.
• People who are generally well enough to carry out daily activities with little or no limitation (based on a standard medical scale called ECOG, with a score of 0 or 1), assessed within 5 days before starting the study treatment.
• People who have not yet had any treatment for their metastatic (spread) melanoma.
• People who previously received certain immune therapy (anti-PD-1) or targeted therapy (anti-BRAF/MEK) as a preventive treatment after surgery, and whose cancer came back more than 6 months after finishing that treatment.
• People who have at least one measurable area of cancer that meets specific size and location requirements used in clinical trials (confirm with trial site).
• People who are willing to provide a fresh tumor tissue sample before starting treatment, or who can provide a stored tissue sample taken after their last cancer treatment — if a biopsy carries too much risk, enrollment may still be possible with supporting documentation from the doctor (confirm with trial site).
• People who have recovered from any side effects of previous cancer treatments, with only mild remaining effects (confirm with trial site for acceptable exceptions such as nerve-related symptoms or hair loss).
• People who have waited at least 4 weeks (or a shorter period based on the specific drug used) since their last cancer treatment before joining the study.
• People with a life expectancy of at least 3 months.
• People whose blood counts and organ function meet specific minimum levels measured within 7 days before starting treatment, including healthy enough blood cell counts, liver function, kidney function, and blood clotting levels (confirm with trial site for exact values).
• People whose blood clotting test results are within acceptable ranges, or within the intended treatment range if they are already taking blood-thinning medication.
• Women who could become pregnant must have a negative pregnancy test within 3 days before starting treatment.
• All participants must agree to follow the contraception requirements outlined in the study protocol.
• People with at least one area of cancer that can be measured or assessed.
• People who have provided written informed consent to participate.

Who may not be able to join:

• People whose melanoma started in the mucous membranes (such as inside the mouth or nasal passages) or in the eye.
• People who have melanoma that has spread to the brain, whether or not it is causing symptoms.
• People with active, known, or suspected autoimmune diseases (some minor conditions such as vitiligo or type 1 diabetes may be acceptable — confirm with trial site).
• People who have had another type of cancer in the past 2 years, with the exception of certain skin cancers or cervical cancer that were completely removed (confirm with trial site for exact exceptions).

Important: Always verify eligibility with the trial site directly before applying.